Evidence map›Paper›PMID 25581283›Full record

ArticleNature communications2015

MARQUIS: a multiplex method for absolute quantification of peptides and posttranslational modifications.

Timothy G Curran, Yi Zhang, Daniel J Ma, Jann N Sarkaria, Forest M White

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 44 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Proteomics of phosphorylation and protein dynamics during fertilization and meiotic exit in theProceedings of the National Academy of Sciences of the United States of America · 2017
    Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Early signaling dynamics of the epidermal growth factor receptor.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Timothy G Curran1] Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA [2] Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Yi ZhangThermo-Fisher Scientific, San Jose, California 95134, USA.
Daniel J MaDepartment of Radiation Oncology, Mayo Clinic, 200 First Street South West, Rochester, Minnesota 55905, USA.
Jann N SarkariaDepartment of Radiation Oncology, Mayo Clinic, 200 First Street South West, Rochester, Minnesota 55905, USA.
Forest M White1] Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA [2] Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Massachusetts Institute of Technology · USMayo Clinic · USThermo Fisher Scientific (United States) · US

Funding

Tumor Cell Networks CenterU54CA112967 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LAUFFENBURGER, DOUGLAS A · 2004 to 2015
$26.2M
Targeted MV-CEA as a Potent Antitumor Agent against GBMP50CA108961 · NCI · MAYO CLINIC ROCHESTER · PI O'NEILL, BRIAN PATRICK · 2004 to 2015
$22.5M
Vanderbilt Proteome Characterization CenterU24CA159988 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI LIEBLER, DANIEL C · 2011 to 2016
$13.9M
Engineered Antibody EGFR Antagonist Cancer TherapeuticsR01CA096504 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI WITTRUP, KARL DANE · 2002 to 2017
$9.7M
Dynamics and Topology of Phosphotyrosine-SH2 Interaction NetworksU01CA154966 · NCI · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI MAYER, BRUCE J., WHITE, FOREST M · 2011 to 2015
$2.4M
Quantitative Analysis of Epidermal Growth Factor Receptor Signaling NetworksR01CA118705 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI WHITE, FOREST M · 2008 to 2012
$1.8M
NCI NIH HHS CA108961NCI NIH HHS P50 CA108961NCI NIH HHS R01 CA096504NCI NIH HHS R01 CA118705NCI NIH HHS U01 CA154966NCI NIH HHS U24 CA159988NCI NIH HHS U54 CA112967
6 · The paper itself

Abstract

Absolute quantification of protein expression and posttranslational modifications by mass spectrometry has been challenging due to a variety of factors, including the potentially large dynamic range of phosphorylation response. To address these issues, we have developed MARQUIS-Multiplex Absolute Regressed Quantification with Internal Standards-a novel mass spectrometry-based approach using a combination of isobaric tags and heavy-labelled standard peptides, to construct internal standard curves for peptides derived from key nodes in signal transduction networks. We applied MARQUIS to quantify phosphorylation dynamics within the EGFR network at multiple time points following stimulation with several ligands, enabling a quantitative comparison of EGFR phosphorylation sites and demonstrating that receptor phosphorylation is qualitatively similar but quantitatively distinct for each EGFR ligand tested. MARQUIS was also applied to quantify the effect of EGFR kinase inhibition on glioblastoma patient-derived xenografts. MARQUIS is a versatile method, broadly applicable and extendable to multiple mass spectrometric platforms.

Indexed as

Protein Processing, Post-TranslationalAnimalsCell Line, TumorComputational BiologyErbB ReceptorsGlioblastomaHumansLigandsMass SpectrometryMiceNeoplasm TransplantationPeptidesPhosphorylationProtein BindingProteomicsSignal TransductionErbB ReceptorsLigandsPeptidesTyrosine

Identifiers

PMID25581283
PMCPMC4293043
OpenAlexW2086150914

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.